Update on capecitabine alone and in combination regimens in colorectal cancer patients

N. Silvestris, E. Maiello, F. De Vita, S. Cinieri, D. Santini, A. Russo, S. Tommasi, A. Azzariti, G. Numico, S. Pisconti, D. Petriella, V. Lorusso, A. Millaku, G. Colucci

Research output: Contribution to journalArticlepeer-review

Abstract

Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients.

Original languageEnglish
JournalCancer Treatment Reviews
Volume36
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Nov 2010

Keywords

  • Adjuvant
  • Bevacizumab
  • Capecitabine
  • Cetuximab
  • Colorectal carcinoma
  • Irinotecan
  • Metastatic
  • Neoadjuvant
  • Oxaliplatin
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Update on capecitabine alone and in combination regimens in colorectal cancer patients'. Together they form a unique fingerprint.

Cite this